Efficacy and Safety of HepaSphere Drug-Eluting Bead Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy as the Second-Line Treatment in Advanced Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 2015;35(9):2155–2166. doi:10.1111/liv.12818
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236. doi:10.1002/hep.20933
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi:10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. doi:10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62(5):1187–1195. doi:10.1016/j.jhep.2015.02.010
   PubMed Web of Science ®Google Scholar
• Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69(1):60–69. doi:10.1016/j.jhep.2018.02.008
   PubMed Web of Science ®Google Scholar
• He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953–960. doi:10.1001/jamaoncol.2019.0250
   PubMed Web of Science ®Google Scholar
• Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized Phase III trial. J Clin Oncol. 2022;40(2):150–160. doi:10.1200/JCO.21.00608
   PubMed Web of Science ®Google Scholar
• Liu BJ, Gao S, Zhu X, et al. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol. 2020;12(6):663–676. doi:10.4251/wjgo.v12.i6.663
   PubMed Web of Science ®Google Scholar
• Liu BJ, Gao S, Zhu X, et al. Combination therapy of chemoembolization and hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis compared with chemoembolization alone: a propensity score-matched analysis. BioMed Res Int. 2021;2021:6670367. doi:10.1155/2021/6670367
   PubMed Web of Science ®Google Scholar
• Liu B, Gao S, Guo J, et al. A novel nomogram for predicting the overall survival in patients with unresectable HCC after TACE plus hepatic arterial infusion chemotherapy. Transl Oncol. 2023;34:101705. doi:10.1016/j.tranon.2023.101705
   PubMed Web of Science ®Google Scholar
• Ge N, Wang H, He C, Wang X, Huang J, Yang Y. Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE? J Interv Med. 2023;6(2):59–63. doi:10.1016/j.jimed.2023.03.001
   PubMedGoogle Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132
   PubMed Web of Science ®Google Scholar
• Pattanayak CW, Rubin DB, Zell ER. Propensity score methods for creating covariate balance in observational studies. Rev Esp Cardiol. 2011;64(10):897–903. doi:10.1016/j.recesp.2011.06.008
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Eng J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, Phase 2-3 study. Lancet Oncol. 2021;22(7):977–990. doi:10.1016/S1470-2045(21)00252-7
   PubMed Web of Science ®Google Scholar
• Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133–1146. doi:10.1016/S0140-6736(23)00961-3
   PubMed Web of Science ®Google Scholar
• Liu BJ, Gao S, Zhu X, et al. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy. 2021;13(17):1395–1405. doi:10.2217/imt-2021-0192
   PubMed Web of Science ®Google Scholar
• Gao S, Zhang PJ, Guo JH, et al. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. World J Gastroenterol. 2015;21(36):10443–10452. doi:10.3748/wjg.v21.i36.10443
   PubMed Web of Science ®Google Scholar
• Patrikidou A, Sinapi I, Regnault H, et al. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Investig New Drugs. 2014;32(5):1028–1035. doi:10.1007/s10637-014-0100-y
   PubMed Web of Science ®Google Scholar
• Qin S, Cheng Y, Liang J, et al. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist. 2014;19(11):1169–1178. doi:10.1634/theoncologist.2014-0190
   PubMed Web of Science ®Google Scholar
• Zhu C, Ren X, Liu D, Zhang C. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Toxicology. 2021;460:152882. doi:10.1016/j.tox.2021.152882
   PubMed Web of Science ®Google Scholar
• Cayet S, Pasco J, Dujardin F, et al. Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: radio-pathological correlation. Eur J Radiol. 2017;94:180–190. doi:10.1016/j.ejrad.2017.06.025
   PubMed Web of Science ®Google Scholar
• Han NY, Park BJ, Kim MJ, Sung DJ, Cho SB. Hepatic parenchymal heterogeneity on contrast-enhanced CT scans following oxaliplatin-based chemotherapy: natural history and association with clinical evidence of sinusoidal obstruction syndrome. Radiology. 2015;276(3):766–774. doi:10.1148/radiol.2015141749
   PubMed Web of Science ®Google Scholar
• Liu S, Bu X, Kan A, et al. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. Cancer Lett. 2022;528:16–30. doi:10.1016/j.canlet.2021.12.026
   PubMed Web of Science ®Google Scholar
• Ma L, Xu A, Kang L, et al. LSD1-demethylated LINC01134 confers oxaliplatin resistance through SP1-induced p62 transcription in HCC. Hepatology. 2021;74(6):3213–3234. doi:10.1002/hep.32079
   PubMed Web of Science ®Google Scholar
• Shi Y, Niu Y, Yuan Y, et al. PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. Nat Commun. 2023;14(1):1932. doi:10.1038/s41467-023-37542-5
   PubMed Web of Science ®Google Scholar